WAVEMAN · COMPANY

AORT · Artivion, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

AORT

Name: ARTIVION, INC. (AORT) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

ARTIVION, INC.

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0000784199

FORM 144 · 6☆ WATCH

INSIDER NET · 180D

-$3.2M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

122

13F, latest reported quarter

REVENUE GROWTH

+13.6%

XBRL, annual

NET MARGIN

2.2%

CONVERSIONS · 180D

codes C/M, not in net · $589.1K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$3.2M over 180 days

-$3.2M over 90 days

below 70% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

122 funds added or opened last quarter

more than 62% of Medical Devices

REVENUE

+13.6% year over year

more than 63% of Medical Devices

MARGIN

2.2% net margin

more than 64% of Medical Devices

BUYBACKS

no share repurchases reported

SHORT

5.5% of shares outstanding short · 4.8 days to cover · settled 2026-07-31

more than 67% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$3.2M across 4 people in 180 days.

122 funds added or opened positions in the latest 13F quarter, of 209 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -41.5%

-41.5%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $3.2M sold by insiders over 180 days, 122 funds added last quarter, $2.5M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, ARTIVION, INC. insiders sold a net $3.2M of stock across 264 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

GREEN ANDREW M

SVP, Regulatory and Quality

SELL

2026-09-03

1,493.0

$38.8K

GREEN ANDREW M

SVP, Regulatory and Quality

SELL

2026-09-02

6,510.0

$177.5K

Mackin James P

President & CEO

SELL

2026-08-19

70,000.0

$2.0M

Berry Lance A

EVP, COO, CFO & Treasurer

SELL

2026-08-14

715.0

$20.4K

GREEN ANDREW M

SVP, Regulatory and Quality

SELL

2026-08-14

616.0

$17.6K

264 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 259 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

6,674,017.0 sh

$150.0M

NOMURA ASSET MANAGEMENT INTERNATIONAL INC.

3,184,974.0 sh

$71.6M

MORGAN STANLEY

2,557,961.0 sh

$57.5M

Juniper Investment Company, LLC

2,019,885.0 sh

$45.4M

VANGUARD CAPITAL MANAGEMENT LLC

2,004,619.0 sh

$45.0M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

GREEN ANDREW M

FILED 2026-09-03

$38.8K

GREEN ANDREW M

FILED 2026-09-02

$177.5K

Stanton Marshall S.

FILED 2026-08-27

$198.7K

Mackin James P

FILED 2026-08-19

$2.1M

GREEN ANDREW M

FILED 2026-08-14

$17.6K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

ALGER WEATHERBIE SPECIALIZED GROWTH FUND

$10.7M POSITION · AS OF 2026-04-30

3.8%

Unusual Whales Subversive Democratic Trading ETF

$6.9M POSITION · AS OF 2026-03-31

2.9%

Thornburg Focus Growth Fund

$4.7M POSITION · AS OF 2026-03-31

2.4%

Osterweis Opportunity Fund

$6.6M POSITION · AS OF 2026-03-31

2.3%

NORTH SQUARE KENNEDY MICROCAP FUND

$541.8K POSITION · AS OF 2026-02-28

1.8%

ROBO Global Healthcare Technology and Innovation ETF

$946.7K POSITION · AS OF 2026-04-30

1.8%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 6 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release

Phase 3

0 ACTIVE

Not applicable

3 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Artivion, Inc. Pac

CYCLE 2026 · $10K SPENT

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Executive pay vs shareholder return · Mr. Mackin

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$6.9M

$17.4M

$2.1M

+93%

+27%

2024

$5.5M

$12.3M

$1.7M

+21%

+17%

2023

$3.2M

$7.2M

$1.2M

-24%

+6%

2022

$7.2M

$4.7M

$1.8M

-49%

-3%

2021

$4.6M

$3.7M

$1.3M

-14%

+19%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$441.3M	$388.5M	$354.0M	$313.8M
GROSS PROFIT	$284.2M	$248.8M	$229.2M	$202.5M
OPERATING INCOME	$33.7M	$38.9M	$5.7M	$6.2M
NET INCOME	$9.8M	$-13.4M	$-30.7M	$-19.2M
EPS (DILUTED)	0.21	-0.32	-0.75	-0.48
OPERATING CASH FLOW	$39.9M	$22.2M	$18.8M	$-5.2M
CASH	$64.9M	$53.5M	$58.9M	$39.4M
LONG-TERM DEBT	$215.1M	$314.2M	$305.5M	$306.5M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE